Trial Profile
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Haemosiderosis
- Focus Adverse reactions
- Acronyms ENTRUST
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 01 Sep 2017 Results published in the Pediatric Blood and Cancer
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 28 Dec 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.